39223-32-0

Usage

Uses

Used in Pharmaceutical Synthesis:
4-(1-methylcyclopropyl)butanoic acid is used as a key intermediate in the synthesis of various pharmaceuticals for its potential biological and pharmacological properties, contributing to the development of new drugs with diverse therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 4-(1-methylcyclopropyl)butanoic acid serves as a crucial component in the production of pesticides and other agrochemicals, leveraging its chemical properties to enhance crop protection and yield.
Used in Chemical Research and Development:
4-(1-methylcyclopropyl)butanoic acid is utilized as a versatile building block in the chemical industry for research and development, allowing scientists to explore and create new molecules with a range of properties and applications, further expanding the horizons of chemical innovation.

InChI:InChI=1/C8H14O2/c1-8(5-6-8)4-2-3-7(9)10/h2-6H2,1H3,(H,9,10)

Upstream product

• 1351684-03-1 C₁₀H₁₈O₂ 
• 1056595-76-6 C₉H₁₆O₂ 
• 39555-01-6 diethyl 2-ethoxycarbonyl-2-methylglutarate 
• 124-38-9 carbon dioxide 
• 39223-31-9 1,5-dichloro-2-chloromethyl-2-methyl-pentane 

Relevant academic research and scientific papers

Discovery of SCH 900271, a potent nicotinic acid receptor agonist for the treatment of dyslipidemia

Structure-guided optimization of a series of C-5 alkyl substituents led to the discovery of a potent nicotinic acid receptor agonist SCH 900271 (33) with an EC50 of 2 nM in the hu-GPR109a assay. Compound 33 demonstrated good oral bioavailability in all species. Compound 33 exhibited dose-dependent inhibition of plasma free fatty acid (FFA) with 50% FFA reduction at 1.0 mg/kg in fasted male beagle dogs. Compound 33 had no overt signs of flushing at doses up to 10 mg/kg with an improved therapeutic window to flushing as compared to nicotinic acid. Compound 33 was evaluated in human clinical trials.

Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia

A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.